Profound's Dec. 31 Tulsa-Pro installed base at 78

Executive Summary

• Profound Medical Corp. surpassed its 2025 installed base goal for the Tulsa-Pro system, reaching 78 installations as of December 31, 2025, exceeding the previous target of 75.
• The company reported a qualified sales pipeline of 97 new systems across verify, negotiate, and contracting stages at year-end.
• CEO Arun Menawat highlighted that the growing installed base is expected to drive higher patient treatment rates and continued growth in high-margin recurring revenue, driven by the procedure's ability to treat a wide range of prostate diseases while preserving patient function.

Key Details

• Installed Base: 78 Tulsa-Pro systems installed as of December 31, 2025.
• Goal Achievement: Surpassed the previously announced goal of 75 installs by the end of 2025.
• Sales Pipeline: 97 new systems classified in the qualified pipeline (verify, negotiate, and contracting stages) at year-end.
• Product Technology: Tulsa-Pro is an AI-powered, MRI-guided, incision-free therapy for prostate disease ablation. It uses real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound, and closed-loop temperature feedback control.
• Clinical Benefits: The procedure is described as "one-and-done," taking a few hours, with no bleeding, no hospital stay, and quick recovery. It aims to preserve urinary continence and sexual function.
• Regulatory Status: Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA.
• Other Products: Profound is also commercializing Sonalleve (CE marked for uterine fibroids, etc., FDA approved for osteoid osteoma) and exploring additional markets for it.
• Future Financials: The company plans to release fourth-quarter and full-year 2025 financial results near the end of February 2026.

Notable Quotes

• "As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high-margin recurring revenue," said Profound's chief executive officer and chairman, Arun Menawat. "That is being driven primarily by the Tulsa procedure's ability to treat an unrivaled range of prostate diseases, severities and aggressions while preserving crucial functions like continence and sexual health of the patient."